| Why carry out this study? |
| Patients with COVID-19 have an increased risk for thrombotic events. |
| Abnormal coagulation markers, including higher levels of d-dimer and fibrinogen, and a prolongation of the prothrombin time, have been demonstrated in these patients. |
| What was learned from the study? |
| COVID-19 patients had lower platelet reactivity compared to healthy controls. |
| Platelet reactivity had a predictive value for total time of hospitalization ≤ 7 or > 7 days. |
| Our findings suggest that platelet reactivity has no role in the pathophysiology of the hypercoagulable state observed in patients with COVID-19. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.